FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057760254> ?p ?o ?g. }

• W2057760254 endingPage "158" @default.
• W2057760254 startingPage "151" @default.
• W2057760254 abstract "In the involved epidermis of patients with atopic dermatitis, changes in the metabolism of eicosanoids with increased quantities of the arachidonic acid (AA)-derived lipoxygenase products have been observed. Free eicosapentaenoic acid (EPA), a fish oil-derived alternative (n-3) fatty acid, may compete with AA, resulting in an anti-inflammatory effect.In a 10-day double-blind, randomized, placebo-controlled trial, 22 patients hospitalized for moderate-to-severe atopic dermatitis were randomly assigned to receive daily infusions of either a n-3 fatty acid-based lipid emulsion (fish oil, 10%; 200 mL/d) or a conventional n-6-lipid emulsion (soybean oil, 10%; 200 mL/d). Topical treatment was restricted to emollients. The severity of disease was evaluated daily with scoring of erythema, infiltration, and desquamation and by subjective patient scoring of clinical manifestations. In addition, plasma-free and total-bound fatty acids and the composition of membrane fatty acids in blood cells (thrombocytes, granulocytes, and erythrocytes), lipid mediators from isolated neutrophils and platelets, and lymphocyte-activation parameters were determined.Twenty patients completed the trial. Marked improvement from baseline was seen in both groups. On days 6, 7, 8, and 10, disease severity score-defined as the sum of all scores-was more pronounced (p < .05) in the n-3 group compared with the n-6 group. Free arachidonic acid in plasma did not change substantially in both groups, whereas plasma-free EPA, total-bound EPA, and the membrane EPA/AA ratio markedly increased in response to n-3-lipid infusion. In parallel, EPA-derived lipid mediators appeared, whereas lymphocyte functions were unaffected. In the post-treatment period (2/4 weeks), relapse was observed in some patients after n-3 psoralene-ultraviolet A (PUVA) infusion, whereas there was a marked long-term improvement in the n-6 group.IV n-3-fatty acid administration is effective in acutely improving the severity of atopic dermatitis, paralleled by changes in plasma and membrane fatty acid composition and lipid mediator synthesis. The long-term beneficial effects of IV n-6 fatty acids should be evaluated further." @default.
• W2057760254 created "2016-06-24" @default.
• W2057760254 creator A5016511599 @default.
• W2057760254 creator A5023729690 @default.
• W2057760254 creator A5038332135 @default.
• W2057760254 creator A5050514045 @default.
• W2057760254 creator A5053873870 @default.
• W2057760254 creator A5071368095 @default.
• W2057760254 creator A5084935661 @default.
• W2057760254 creator A5085398239 @default.
• W2057760254 date "2002-05-01" @default.
• W2057760254 modified "2023-10-12" @default.
• W2057760254 title "A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis" @default.
• W2057760254 doi "https://doi.org/10.1177/0148607102026003151" @default.
• W2057760254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12005454" @default.
• W2057760254 hasPublicationYear "2002" @default.
• W2057760254 type Work @default.
• W2057760254 sameAs 2057760254 @default.
• W2057760254 citedByCount "65" @default.
• W2057760254 countsByYear W20577602542012 @default.
• W2057760254 countsByYear W20577602542013 @default.
• W2057760254 countsByYear W20577602542014 @default.
• W2057760254 countsByYear W20577602542015 @default.
• W2057760254 countsByYear W20577602542016 @default.
• W2057760254 countsByYear W20577602542017 @default.
• W2057760254 countsByYear W20577602542018 @default.
• W2057760254 countsByYear W20577602542019 @default.
• W2057760254 countsByYear W20577602542020 @default.
• W2057760254 countsByYear W20577602542021 @default.
• W2057760254 countsByYear W20577602542022 @default.
• W2057760254 countsByYear W20577602542023 @default.
• W2057760254 crossrefType "journal-article" @default.
• W2057760254 hasAuthorship W2057760254A5016511599 @default.
• W2057760254 hasAuthorship W2057760254A5023729690 @default.
• W2057760254 hasAuthorship W2057760254A5038332135 @default.
• W2057760254 hasAuthorship W2057760254A5050514045 @default.
• W2057760254 hasAuthorship W2057760254A5053873870 @default.
• W2057760254 hasAuthorship W2057760254A5071368095 @default.
• W2057760254 hasAuthorship W2057760254A5084935661 @default.
• W2057760254 hasAuthorship W2057760254A5085398239 @default.
• W2057760254 hasConcept C126322002 @default.
• W2057760254 hasConcept C142724271 @default.
• W2057760254 hasConcept C168563851 @default.
• W2057760254 hasConcept C181199279 @default.
• W2057760254 hasConcept C185592680 @default.
• W2057760254 hasConcept C19038510 @default.
• W2057760254 hasConcept C203014093 @default.
• W2057760254 hasConcept C204787440 @default.
• W2057760254 hasConcept C27081682 @default.
• W2057760254 hasConcept C2776091944 @default.
• W2057760254 hasConcept C2776685179 @default.
• W2057760254 hasConcept C2776914184 @default.
• W2057760254 hasConcept C2777171753 @default.
• W2057760254 hasConcept C2777300220 @default.
• W2057760254 hasConcept C2778078955 @default.
• W2057760254 hasConcept C2778329239 @default.
• W2057760254 hasConcept C2779946292 @default.
• W2057760254 hasConcept C2909208804 @default.
• W2057760254 hasConcept C3020713888 @default.
• W2057760254 hasConcept C505870484 @default.
• W2057760254 hasConcept C543025807 @default.
• W2057760254 hasConcept C55493867 @default.
• W2057760254 hasConcept C71924100 @default.
• W2057760254 hasConcept C86803240 @default.
• W2057760254 hasConcept C90924648 @default.
• W2057760254 hasConceptScore W2057760254C126322002 @default.
• W2057760254 hasConceptScore W2057760254C142724271 @default.
• W2057760254 hasConceptScore W2057760254C168563851 @default.
• W2057760254 hasConceptScore W2057760254C181199279 @default.
• W2057760254 hasConceptScore W2057760254C185592680 @default.
• W2057760254 hasConceptScore W2057760254C19038510 @default.
• W2057760254 hasConceptScore W2057760254C203014093 @default.
• W2057760254 hasConceptScore W2057760254C204787440 @default.
• W2057760254 hasConceptScore W2057760254C27081682 @default.
• W2057760254 hasConceptScore W2057760254C2776091944 @default.
• W2057760254 hasConceptScore W2057760254C2776685179 @default.
• W2057760254 hasConceptScore W2057760254C2776914184 @default.
• W2057760254 hasConceptScore W2057760254C2777171753 @default.
• W2057760254 hasConceptScore W2057760254C2777300220 @default.
• W2057760254 hasConceptScore W2057760254C2778078955 @default.
• W2057760254 hasConceptScore W2057760254C2778329239 @default.
• W2057760254 hasConceptScore W2057760254C2779946292 @default.
• W2057760254 hasConceptScore W2057760254C2909208804 @default.
• W2057760254 hasConceptScore W2057760254C3020713888 @default.
• W2057760254 hasConceptScore W2057760254C505870484 @default.
• W2057760254 hasConceptScore W2057760254C543025807 @default.
• W2057760254 hasConceptScore W2057760254C55493867 @default.
• W2057760254 hasConceptScore W2057760254C71924100 @default.
• W2057760254 hasConceptScore W2057760254C86803240 @default.
• W2057760254 hasConceptScore W2057760254C90924648 @default.
• W2057760254 hasIssue "3" @default.
• W2057760254 hasLocation W20577602541 @default.
• W2057760254 hasLocation W20577602542 @default.
• W2057760254 hasOpenAccess W2057760254 @default.
• W2057760254 hasPrimaryLocation W20577602541 @default.
• W2057760254 hasRelatedWork W2004313032 @default.
• W2057760254 hasRelatedWork W2030059543 @default.
• W2057760254 hasRelatedWork W2360683763 @default.

• next